These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 12373528

  • 1. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L.
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [Abstract] [Full Text] [Related]

  • 2. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD, Chase TN.
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW.
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [Abstract] [Full Text] [Related]

  • 7. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
    Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM.
    Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Problems with current pharmacologic treatment of Parkinson's disease.
    Hurtig HI.
    Exp Neurol; 1997 Mar; 144(1):10-6. PubMed ID: 9126144
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 15. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J.
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [Abstract] [Full Text] [Related]

  • 16. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 17. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD.
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [Abstract] [Full Text] [Related]

  • 18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 19. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ.
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM.
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.